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Targeted therapyHsp90 is an ATP dependent molecular chaperone protein which integrates multiple oncogenic pathways. As
such, Hsp90 inhibition is a promising anti-cancer strategy. Several inhibitors that act on Hsp90 by binding to
its N-terminal ATP pocket have entered clinical evaluation. Robust pre-clinical data suggested anti-tumor
activity in multiple cancer types. Clinically, encouraging results have been demonstrated in melanoma,
acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple
myeloma. In breast cancer, proof-of-concept was demonstrated by ﬁrst generation Hsp90 inhibitors in com-
bination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2)+metastatic breast
cancer. There are a multitude of second generation Hsp90 inhibitors currently under investigation. To date,
however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.
This review summarizes the current status of both ﬁrst and second generation Hsp90 inhibitors based on
their chemical classiﬁcation and stage of clinical development. It also discusses the pharmacodynamic assays
currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of
Hsp90 inhibitors. Ultimately, these efforts will aid in maximizing the full potential of this class of agents.
This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Hsp90 is a chaperone that functions in the correct folding of its
client proteins to their active conformation. Hsp90 is an ATPase and
accomplishes its role through a complex cycle regulated by the bind-
ing and hydrolysis of ATP as well as by numerous co-chaperones
(Hsp70, HOP, Cdc37, p23, Aha1). Inhibition of the Hsp90 chaperone
cycle causes client proteins to undergo ubiquitination and subsequent
degradation by the proteasome [1,2]. Because many of its clients
include oncoproteins with important functions in the development
and promotion of cancer, Hsp90 is an important target in cancer
therapy [3].
The discovery of Hsp90 as the target of anticancer activity of gel-
danamycin (GM) (Fig. 1) sparked much interest in the inhibition of
Hsp90 as a strategy for the treatment of cancer. This interest has
resulted in intense efforts from both industry and academic centers
to develop clinically viable small molecule Hsp90 inhibitors [4]. As
a result of these efforts, there are numerous small-molecule Hsp90
inhibitors that are currently undergoing clinical investigation in a
wide range of malignancies. Of the numerous ways of potentiallyhock Protein 90 (HSP90).
Pharmacology and Chemistry,
l rights reserved.inhibiting the chaperone cycle, it should be noted that each of the
molecules currently in clinical trials inhibits the ATPase activity of
Hsp90 by binding to the N-terminal domain nucleotide binding pock-
et [5,6].
The clinical development of Hsp90 inhibitors, from GM to the
newest agents, has been and will continue to be driven by the optimi-
zation of pharmaceutical properties including pharmacokinetic,
pharmacodynamic and toxicological. Even though there are currently
no approved Hsp90 targeted agents, research during this past decade
has been very promising as there has been considerable progress on
many fronts including improved formulations and the introduction
of chemically distinct Hsp90 inhibitors with improved properties.
These advances together with the increased biological knowledge of
Hsp90 can help to fulﬁll the promise of this target and potentially
result in the approval of the ﬁrst-in-class agent.
2. Clinical studies with Hsp90 inhibitors in cancers
While the molecules currently advanced to clinical trials consti-
tute a diverse array of structures, a close inspection of them shows
that they can in general be classiﬁed according to their similarity
to GM, radicicol (RD) or to the purine-scaffold. Only SNX-5422 falls
outside any of these designations (Fig. 1 and Table 1). As is often
the case in drug discovery, natural products play a prominent role
in the discovery of lead agents. In the case of Hsp90, GM, RD and
743K. Jhaveri et al. / Biochimica et Biophysica Acta 1823 (2012) 742–755ATP have each had a profound effect on the development of small-
molecule Hsp90 inhibitors. While none of these are suitable as a
clinical agent, they have each served as good leadmolecules or starting
points for most of the agents in clinical trials.
2.1. Geldanamycin derivatives
GM is a benzoquinone ansamycin ﬁrst isolated from a fermenta-
tion broth of Streptomyces hygroscopicus in 1970 (Fig. 1) [7]. Original-
ly pursued as an antibiotic, its anticancer properties were discovered
following a phenotypic screening of compounds capable of reversing
v-src oncogene transformed cells [8]. Initially, it was believed to be a
direct inhibitor of src kinase, however, it was later shown to directly
bind to Hsp90 and interfere with Hsp90-v-src heterocomplex forma-
tion [9]. Further work showed that GM inhibits the ATPase activity of
Hsp90 by competing with ATP for binding to the N-terminal domain
nucleotide binding pocket [10,11], resulting in ubiquitin mediated
proteasomal degradation of its client proteins [1,2,12].
Despite its potent anti-tumor effects, GM was never evaluated in
clinical trials because of its poor “drug-like” properties including
poor solubility, limited in vivo stability and signiﬁcant hepatotoxicity
in animals [13,14]. Structural features of GM include a quinone ring
(depicted in blue, Fig. 1), moiety contributing to the observed hepato-
toxicity, along with a pendant macrocycle containing a carbamate
group essential for binding (Fig. 1). Additionally, GM contains a
non-essential methoxy group on C-17 of the quinone ring (depicted
in red, Fig. 1) that can readily be substituted with amines. This ap-
proach was used in an attempt to overcome the liabilities associated
with GM and resulted in the preparation of many analogs including
those that have entered clinical trials (Table 1, entry 1–4).
2.1.1. 17-AAG (17-allyl-17-demethoxygeldanamycin)
Substitution in GM of the methoxy group with an allylamino group
resulted in 17-AAG (Table 1, entry 1), a compound with biological
activity similar to GM but with an improved toxicity proﬁle [15].
In fact, 17-AAG was the ﬁrst Hsp90 inhibitor selected by the CancerO
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Fig. 1. Structures of representative Hsp90 inhibitor chemical classes.Therapy Evaluation Program (CTEP) of the National Cancer Institute
(NCI) for clinical studies in cancer and provided proof-of-concept for
Hsp90 inhibition in humans. In these studies, 17-AAG has been evaluat-
ed using weekly, weekly for 3 weeks (28 day cycle), daily×5 (21 day
cycle), and daily×3 (14 day cycle), twice weekly (day 1, 4), and on
days 1, 4, 8, 11 (21 day cycle) schedules [16–23]. Toxicity of 17-AAG
in these trials was dose and schedule dependent, with hepatotoxicity
being more prominent with daily administration. Other toxicities
were primarily diarrhea and fatigue. Because of its poor solubility and
in order to administer 17-AAG intravenously, the NCI had developed a
dimethyl sulfoxide and egg phospholipid vehicle, however, at doses
greater than 100 mg/m2, the toxicities due to this vehicle (bad odor,
nausea, anorexia) were as signiﬁcant as the toxicities from the drug
itself. Pharmacokinetic (PK) studies that were incorporated in these
phase I trials suggested that serum concentrations greater than those
required for depletion of Hsp90 client proteins in vitro and in xenograft
models could be achieved at well-tolerated doses and schedules.
Pharmacodynamic (PD) assays in these trials included peripheral
blood mononuclear cell (PBMC) studies and limited tumor biopsies,
as discussed further in Section 3 of this review [16,20]. Despite the
evidence of at least partial target modulation in these phase I trials,
there were no complete or partial responses (CR or PR respectively)
by RECIST (Response Evaluation Criteria in Solid Tumors). Several
patients with melanoma, breast cancer, prostate cancer and renal
cell carcinoma did have stable disease (SD). Disappointingly, single
agent phase II studies using 17-AAG once weekly (300–450 mg/m2)
in prostate cancer or melanoma or twice weekly (220 mg/m2) in
renal cell carcinoma patients also showed no objective responses
with this dose and schedule of 17-AAG [24–26].
In patients heavily pretreated for relapsed/refractory multiple my-
eloma, single agent 17-AAG administered on days 1, 4, 8, and 11 every
3 weeks was well tolerated with one minimal response (MR), with a
progression-free survival (PFS) of 3 months, a 41% decline in urine M
protein, and a 33% decrease from baseline in serumM protein. Fifteen
other patients had SD with a median PFS of 2.1 months [27].
Limited success of 17-AAG in these studies was attributed to poor
solubility, poor patient enrichment for those most likely to beneﬁt
based on preclinical experience (for e.g. patients with HER2 ampliﬁed
breast cancer), suboptimal target inhibition and off-target toxicities
from 17-AAG and its DMSO formulation.
Improving the formulation and the delivery of 17-AAG in disease
speciﬁc population has led to encouraging results. Kosan Biosciences
developed a Cremophor containing formulation of 17-AAG (tanespi-
mycin, KOS-953) as an injectable suspension. The ﬁrst solid tumor
trial with this formulation was a phase I/II study of 17-AAG and
trastuzumab. The phase I portion was open to all tumor histologies.
Of the 25 patients enrolled, 15 had HER2+ metastatic breast cancer.
Patients were enrolled onto 4 dose cohorts (225–450 mg/m2) and
treated with both agents on a weekly schedule. Dose limiting toxicity
(DLT) included fatigue, nausea, anorexia and thrombocytopenia. With
the weekly schedule, hepatotoxicity was minimal. Anti-tumor activity
was seen only in patients with HER2+ metastatic breast cancer with
1 conﬁrmed PR, 4 MR and 4 patients with SD for more than 4 months
[28]. In order to obtain a more precise estimate of activity, the phase II
trial enrolled 31 patients with HER2+ metastatic breast cancer who
were previously refractory to trastuzumab therapy [29]. Patients
were treated with 450 mg/m2 of tanespimycin with trastuzumab
weekly. The primary endpoint was response rate (RR) by RECIST
criteria. Most common toxicities were diarrhea, fatigue, nausea
and headache. The overall RR was 22% and the clinical beneﬁt rate
(CR+PR+SD) was 59% with a median PFS of 6 months (95% CI:
4–9) and median overall survival (OS) of 17 months (95% CI:
16–28). The effectiveness noted in this phase II trial could be due to
potent target degradation (i.e. HER2+) due to the combination of
these drugs and perhaps because Hsp90 inhibitors can overcome or
delay the initial resistance to trastuzumab [30].
able 1
sp90 inhibitors in clinical evaluation.
Inhibitor Company Structure Class Route Phase
1. Tanespimycin
(17-AAG, KOS-953)
Kosan Biosciences/
Bristol-Myers-Squibb
GM IV III
2. Alvespimycin
(17-DMAG)
Kosan Biosciences/
Bristol-Myers-Squibb
GM IV I
Oral
3. Retaspimycin
(IPI-504)
Inﬁnity Pharmaceuticals GM IV III
4. IPI-493 Inﬁnity Pharmaceuticals GM Oral I
5. CNF2024/BIIB021 Biogen Idec Purine Oral II
6. MPC-3100 Myriad Pharmaceuticals/
Myrexis
Purine Oral I
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Table 1 (continued)
Inhibitor Company Structure Class Route Phase
7. Debio 0932
(CUDC-305)
DebioPharm Purine-like Oral I
8. PU-H71 Samus Therapeutics Purine IV I
9. Ganetespib
(STA-9090)
Synta Pharmaceuticals Not reported Resorcinol–Triazole IV II
10. NVP-AUY922
(VER-52269)
Novartis Resorcinol–Isoxazole IV II
11. HSP990 Novartis Not reported but claimed as a follow
up compound to NVP-AUY922
Not reported Oral I
12. KW-2478 Kyowa Hakko
Kirin Pharma
Resorcinol IV I
13. AT13387 Astex Resorcinol IV I
Oral
(continued on next page)
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Table 1 (continued)
Inhibitor Company Structure Class Route Phase
14. SNX-5422 Serenex/Pﬁzer Indazol-4-one Oral I
15. DS-2248 Daiichi Sankyo Inc Not reported Not reported Oral I
16. XL888 Exelixis Not reported Not reported Oral I
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synergistic effect of anti-tumor activity was also noted with combina-
tion of tanespimycin and bortezomib in multiple myeloma. In a phase
I/II study, 72 patients with relapsed and refractory multiple myeloma
were treated with this combination (tanespimycin 100–340 mg/m2
and bortezomib 0.7–1.3 mg/m2) [31]. The highest dose for tanespi-
mycin tested in this study was 340 mg/m2 and no DLT was identiﬁed.
Importantly, there were no cases of grade 3 peripheral neuropathy.
Anti-tumor activity was observed with overall RR≥MR in 48% of
bortezomib-naive, 22% of bortezomib-pretreated and 13% of bortezo-
mib refractory patients; median duration of response for all re-
sponders was 12 months. The phase II study of this combination,
although an extension of the phase I/II study, deployed a broader
tanespimycin dosage range (50–340 mg/m2). Unlike the previously
described phase I/II study, this phase II trial involved a slightly differ-
ent population, in that they excluded bortezomib—naïve patients and
patients with no measurable multiple myeloma [32]. Twenty-two
patients were administered with this combination regimen on days
1, 4, 8, 11 in each 3-week cycle. Most common adverse events were
fatigue, diarrhea, nausea, constipation and vomiting. Liver toxicity relat-
ed adverse eventswere noted in 4 patients, whichwasmanageable and
reversible, and thrombocytopenia was the most common hematologi-
cal adverse event. Peripheral neuropathy is a signiﬁcant toxicity of
single agent bortezomib therapy. However, there were low rates of
peripheral neuropathy, in particular grade 3 peripheral neuropathy,
seen with combination of tanespimycin and bortezomib. This favorable
effect of both decreased rate and severity of peripheral neuropathy
correlated well with the pre-clinical observation that tanespimycin
has a neuroprotective effect against bortezomib-induced peripheral
neuropathy [33]. Overall RR was 14% (2 PR and 1MR) and an additional
10 patients had SD. This led to further development of tanespimycin in
phase III trials for potential treatment of multiple myeloma. However,
Kosan, acquired by Bristol-Myers-Squibb in 2008, suspended this
phase III trial for non-clinical reasons [34].
Because Hsp90 can protect cells under stress conditions, Hsp90
inhibitors have the ability to sensitize cells to the toxic effects of
chemotherapy (including taxanes, anthracyclines, nucleoside analogs
and topoisomerase I inhibitors and lead to synergistic activity) and
radiation therapy. One possible mechanism by which Hsp90 inhibi-
tors are thought to enhance the cytotoxicity of chemotherapy is by
depleting the checkpoint kinase1 (chk1). Chk1 is a Hsp90 client pro-
tein that regulates progression through the cell cycle and is particu-
larly critical for the S and G2-M phases [35]. Hsp90 inhibitors
degrade chk1 which in turn abrogates G1/S arrest induced by gemci-
tabine [35] and G2-M checkpoint induced by topoisomerase I inhibi-
tors such as irinotecan [36]. Nguyen et al. showed 5–22 fold
enhancement of paclitaxel cytotoxicity when combined with Hsp90
inhibitors [37]. Breast cancer cell lines exposed to Hsp90 inhibitorswere sensitized to the apoptotic effects of paclitaxel by activation
of caspase-3 and −9 [38]. Cells with intact retinoblastoma gene
(RB) that was exposed to 17-AAG followed by paclitaxel underwent
G1 arrest and enhanced apoptosis. This schedule dependence was
not noted in cells harboring a mutated RB. Akt inactivation is another
mechanism bywhich Hsp90 inhibitors sensitize tumor cells to induction
of apoptosis by paclitaxel [39]. These studies formed the rationale for
combination phase I trials of 17-AAG with paclitaxel [38,40], docetaxel
[41], cisplatin [42], gemcitabine-cisplatin [43] and irinotecan [44].
Similarly, Hsp90 inhibitors are thought to enhance the radiosensi-
tivity of many tumor cell lines. Raf-1, Akt and HER2 are radioresponse
proteins that protect against radiation induced cell death. Hsp90 inhi-
bition causes degradation of the radioresponse proteins, increases
apoptosis and enhances G2 arrest [45]. Lastly, in an attempt to show
synergistic activity by simultaneously inhibiting the Raf-signaling
pathway, a phase I trial evaluated the combination of 17-AAG with
Sorafenib and showed clinical activity in renal cell carcinoma and
melanoma patients [46].
Alternatively, agents such as cisplatin may enhance the activity of
Hsp90 inhibitors [47]. Under non-stress conditions, heat shock factor
1 (HSF1) binds with Hsp90, but when an Hsp90 inhibitor blocks the
target, HSF1 is released, thereby causing a heat shock response that
potentially limits the effect of Hsp90 inhibition. Cisplatin blocks the
HSF1 mediated heat shock response by blocking HSF1 binding to
the promoter region of the transcription factor [42,48].
Despite, these early encouraging results, the development of
17-AAG was halted in July 2008. However, more recently, 17-AAG
was successfully converted to nanoparticle albumin-bound, nab-
17AAG/ABI-1010 to improve the safety and efﬁcacy over their surfac-
tant and solvent based counterparts [49]. This agent is currently being
evaluated in a phase I trial in combination with Abraxane in patients
with advanced solid tumors. Patients will be administered ABI-1010
intravenously weekly for 3 weeks of a 28-day cycle; results of this
trial are awaited [50].
2.1.2. 17-DMAG (17-desmethoxy-17-N,N-dimethylaminoethylaminogel
danamycin)
Substitution of the C-17 methoxy group of GM with N,
N-dimethylethylamine resulted in 17-DMAG (Table 1, entry 2). The
presence of an ionizable amino group resulted in increased water
solubility, better oral bioavailability and equal or greater anti-tumor
activity compared to 17-AAG [51,52]. 17-DMAG was developed by
the NCI and Kosan and entered phase I clinical trials in 2005. Various
schedules were evaluated including twice weekly [53], daily×3 or
5 days every 3 weeks (1.5–46 mg/m2) [54], weekly (2.5–80 mg/m2)
[55], twice weekly×2 weeks and every 3 weeks (8–32 mg/m2)[56].
Toxicity in these trials included peripheral neuropathy [53], renal
dysfunction [53,55], fatigue [55], cardiotoxicity [56], ocular adverse
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nitis with dyspnea and thrombocytopenia [56]. Efﬁcacy assessment
included 1 CR (castrate refractory prostate cancer) and 1 PR (melano-
ma) [55] and 3 CR in acute myeloid leukemia [56]. There was also one
phase I trial of orally administered 17-DMAG wherein patients were
administered 17-DMAG either daily or every other day for 4 out of
6 weeks [57]. In the 28 patients treated, no DLT was observed and
common drug-related toxicities included fatigue, anorexia, protein-
uria and peripheral edema. Bioavailability in 14 patients was 51%
and 49% on day 1 and 21 respectively and was not dose-dependent.
Early signs of activity included SD in hemangioendothelioma, mela-
noma and renal cell carcinoma.
17-DMAG (60–100 mg/m2), administered weekly has also been
investigated in combination with trastuzumab (phase I study) in 28
patients with metastatic breast cancer and metastatic ovarian cancer.
DLT was grade 3 keratitis, which was reversible, and 1 patient had a
decline in left ventricular ejection fraction. Anti-tumor activity was
seen in patients with HER2+ metastatic breast cancer (1 PR, 1 MR
and 5 patients with SD). Tumor regression including CR was also
noted in 1 patient with HER2+ metastatic breast cancer and another
patient with ovarian cancer (HER2 status unknown) [58].
Despite the CR with 17-DMAG in patients with acute myeloid
leukemia, Kosan discontinued its development in 2008 to “commit
resources to the development of 17-AAG for the treatment of breast
cancer as a result of a comparative analysis with 17-AAG based on
several factors, including clinical experience to date, strength of intel-
lectual property protection and risk, and time to commercialization”
[59].
2.1.3. IPI-504 [17-allylamino-17-demethoxygeldanamycin hydroquinone
hydrochloride]
In a different approach, Inﬁnity Pharmaceuticals developed
IPI-504 (retaspimycin) (Table 1, entry 3), a new GM analog, which
is the water-soluble hydroquinone hydrochloride salt derivative of
17-AAG [60]. IPI-504 can be prepared by reduction of 17-AAG with
sodium dithionite followed by conversion to its hydrochloride salt.
IPI-504 and 17-AAG actually exist in a redox equilibrium in vivo
between the hydroquinone (as in IPI-504) and quinone (as in 17-
AAG) forms through the action of oxidoreductases. The hydroquinone
form in IPI-504 is a more potent inhibitor of Hsp90 and is likely the
more relevant form in vivo. Additionally, since the quinone ring has
been identiﬁed as a primary cause for the hepatotoxicity of GM, its re-
duction to a hydroquinone has predictably resulted in diminished
toxicity. For a number of reasons, including improved PK and toxicity
properties, IPI-504 appears to be the most promising inhibitor de-
rived from the ansamycin class [61]. Various phase I–III trials have
been conducted in patients with multiple myeloma, non-small cell
lung cancer, castrate resistant prostate cancer, breast cancer and gas-
trointestinal stromal tumor.
In the phase I trial in patientswith relapsed and refractorymultiple
myeloma, IPI-504 was infused on days 1, 4, 8, 11 of a 21-day cycle. The
primary objective was MTD which was determined to be 400 mg/m2
[62].
A phase I/II trial was conducted in 12 patients with non-small cell
lung cancer after they had progressed on epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI). Patients were
administered with IPI-504 twice weekly on a 4 week cycle at doses
(150 to 300 mg/m2). DLT was increased liver enzymes and fatigue.
Of the 9 patients who were evaluable, 7 had best response of SD. Of
the 4 patients who had evaluable disease by 18F-ﬂuorodeoxyglucose
(FDG) positron emission tomography (PET), 2 had SD and 2 had PR
[63]. This promising activity led to the phase II portion of the study
which evaluated 76 patients at 400 mg/m2 administered twice week-
ly on a 21 day cycle [64]. The primary objective was overall RR;
secondary aims included safety, PFS and analysis by molecular sub-
types. The most common side effects were fatigue, diarrhea andnausea. Grade 3 or higher liver function abnormalities were observed
in 9 patients. Overall RR was 7% (5 PR) with 10% in patients who were
EGFR-wild type and 4% in those who had EGFR mutations. Although
the target overall RR was 20% for the two EGFR groups, 2 of the 3
patients with oncogenic rearrangement of the anaplastic lymphoma
kinase (ALK) gene also had PR and the third had SD for 7.2 months
with 24% reduction in tumor size. This was the ﬁrst trial that showed
that Hsp90 inhibitors have clinical activity in non-small cell lung
cancer, particularly among those with ALK rearrangements [64].
A phase Ib trial evaluated IPI-504 in combination with docetaxel in
16 patients with advanced solid tumors of which 6 were non-small
cell lung cancer. Patients were treated with 300–550 mg/m2 of IPI-
504 in combination with 75 mg/m2 of docetaxel on a once every
3 weeks schedule. DLT included fatigue, neutropenia, asymptomatic
bradycardia, increase in liver enzymes with acute respiratory distress
syndrome; all of which were reversible on trial. MTDwas identiﬁed as
450 mg/m2 [65]. In the expansion phase, 23 patients with non-small
cell lung cancer were treated with 300 mg/m2 of IPI-504 in combina-
tion with 75 mg/m2 of docetaxel weekly in a 21-day cycle. Among the
23 patients, there was no drug-related hepatotoxicity. Gastrointesti-
nal toxicity was low grade and easily manageable. The overall RR
was 26% (6 PR, 7SD). Higher response rates were seen in heavy
smokers and those with squamous cell histology. Based on these
data, an adaptive randomized phase II study is underway comparing
IPI-504 and docetaxel versus placebo+docetaxel in pretreated
patients with non-small cell lung cancer and a smoking history. This
trial is designed to identify and validate potential predictive bio-
markers of the activity of combination treatment [66].
A single agent phase II trial evaluated the safety and efﬁcacy of
IPI-504 in two groups of men with castrate resistant prostate cancer.
Group A was chemotherapy-naïve patients and group B included
patients who had disease progression on previous docetaxel-based
therapy. IPI-504 was administered at 400 mg/m2 twice weekly on a
21-day cycle. Of the 19 patients enrolled in this study, 15 had prior
docetaxel-based therapies. There was no prostate speciﬁc antigen
(PSA) or RECIST responses although one patient remained on study
for 9 cycles with 48% PSA decline. Serious adverse events were
noted in group B which included grade 5 hepatic failure and grade 5
ketoacidosis and the study concluded that further evaluation in this
population was not warranted [67].
Recently, the results of a phase II trial of IPI-504 in combination
with trastuzumab in patients with metastatic HER2+ metastatic
breast cancer were presented at the 2011 Annual ASCO scientiﬁc
meeting. 26 patients were treated with 300 mg/m2 of IPI-504 weekly
in combination with trastuzumab 6 mg/kg once every 3 weeks. End-
points of this study included overall RR and tolerability of IPI-504.
The trial used a Simon two-stage design with prespeciﬁed criteria; if
the DLT rate was b25% and at least 2 responses were seen, then the
trial would be expanded. No DLTs were reported. The most common
adverse events noted were fatigue, nausea and diarrhea. Among the
20 patients evaluable for efﬁcacy, 1 PR was observed and 1 patient
had SD for 6 months. Thus, there was modest clinical activity but
the trial did not meet the prespeciﬁed criteria for trial expansion [68].
Patients with TKI-resistant gastrointestinal stromal tumor were
treated with IPI-504 in a phase I dose-escalation trial. The initial
trial design included only 45 patients with metastatic and unresect-
able gastrointestinal stromal tumor but later, 18 patients with soft tis-
sue sarcomas were also included. IPI-504 was evaluated in ﬁve dose
levels administered either twice weekly for 2 weeks followed by
1 week off or twice weekly for 3 weeks in continuous 21 day cycles.
The objectives of this trial were to determine the MTD, ﬁnd the
dose and schedule for subsequent trials and to assess the biologic
activity of IPI-504 with anatomic and FDG-PET imaging. FDG-PET im-
aging was done at baseline, day 11 and 21. IPI-504 was well tolerated
up to 400 mg/m2 twice weekly followed by 1 week off. DLT was head-
ache and myalgia. Other common adverse events included fatigue,
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for efﬁcacy on this schedule, 67% had SD and 3% had a PR. For the
18 patients evaluable by FDG-PET, 22% had a PET PR and 66% had
SD. Median PFS was 12 weeks [69].
The RING (retaspimycin in GIST) trial was an international phase
III, double blinded, placebo controlled trial of IPI-504 in patients
with refractory gastrointestinal stromal tumor that had failed previ-
ous therapies with either imatinib or sunitinib. There was no limit
on previous therapies. Target enrollment was 200 patients, however
the study was terminated after 46 patients were enrolled as a higher
mortality rate was observed for patients in the treatment arm. Review
of the patients' demographics revealed that the higher mortality rate
was observed in those enrolled in the treatment arm who had
received three or more therapies since their initial diagnosis and
had more advanced disease compared to patients enrolled in the ear-
lier IPI-504 trials [70]. Due to the safety concerns and the increased
mortality rate in this population, and because 17-AAG and IPI-504
are interconvertible in vivo, the phase III trial of 17-AAG was also
terminated [61].
2.1.4. IPI-493 (17-desmethoxy-17-amino geldanamycin)
IPI-493, the primary active, long-lived metabolite of 17-AAG
was developed by Inﬁnity Pharmaceuticals as an oral formulation
(Table 1, entry 4). However, IPI-493 suffers from poor pharmaceutical
properties including low solubility and is difﬁcult to administer in
pharmacologically relevant doses. Because drug exposure of IPI-504
was superior to IPI-493 Inﬁnity has halted the development of this
agent to focus exclusively on retaspimycin [71].
2.2. Purine and purine-like analogs
The rational design of Hsp90 inhibitors became possible following
the availability of X-ray crystal structures of Hsp90 bound to ATP/ADP
as well as to GM and RD. Hsp90 has a unique fold among most other
ATPases resulting in a distinctive conformation adopted by bound
nucleotide that has enabled for its selective inhibition by small-
molecules over other ATP/ADP binding proteins [72]. Taking advan-
tage of this unique fold and using a structure-based approach, Chiosis
et al. designed the ﬁrst reported synthetic Hsp90 inhibitor, PU3
(Fig. 1), based on the purine-scaffold by incorporating features that
enabled the molecule to adopt a bent conformation [73]. As the pro-
totype for the purine-scaffold class, PU3 has been optimized by
numerous groups through a variety of strategies to result in potent
and selective inhibitors with improved pharmaceutical properties.
Those that have advanced to clinical trials include the purines
CNF2024/BIIB021, MPC-3100, and PU-H71 as well as the purine-like
Debio 0932 (CUDC-305) (Table 1, entry 5–8). Each of these molecules
has in common an –NH2 group attached to a purine or purine-like
core and an aryl moiety separated by approximately 5 Å as critical
elements for binding to Hsp90. The aryl moiety is attached to the
purine or purine-like core by a one atom linker [74].
2.2.1. CNF 2024/BIIB021
CNF 2024/BIIB021 was discovered and ﬁrst developed by Con-
forma Therapeutics and later by Biogen Idec (Table 1, entry 5)
[75–77]. CNF2024/BIIB021 is unique amongst the other members in
this class in that the aryl moiety is attached to the 9-position of the
purine. In order to maintain the critical distance of 5 Å, the amino
group was moved to the 2-position.
This agent has been evaluated in phases I and II clinical trials. A
phase I clinical trial evaluated BIIB021 administered orally daily
for 3 weeks in a 28-day cycle in patients with chronic lymphocytic
leukemia versus orally twice weekly for 3 weeks in a 28-day cycle
in patients with advanced solid tumors. MTD was determined at
800 mg twice weekly and DLT was syncope and dizziness in patients
with advanced solid tumors. Other grade 3 or 4 toxicities includedfatigue, hyponatremia and hypoglycemia. There was one incidence
of grade 3 abnormal liver enzymes in a patient with chronic lympho-
cytic leukemia. Efﬁcacy assessment revealed that one patient with
chronic lymphocytic leukemia had a 39% reduction in the lymph
node size at 25 mg dose and 11 of 16 evaluable patients with solid
tumors had SD [78].
Another phase I dose-escalation trial evaluated BIIB021 in combi-
nation with trastuzumab in patients with HER2+ metastatic breast
cancer. Primary endpoint was to evaluate the safety and tolerability
of BIIB021 when administered orally twice weekly in combination
with 6 mg/kg trastuzumab every 3 weeks. MTD was determined at
600 mg twice weekly. DLT were diarrhea and partial seizure that pre-
sented as aphasia. Other frequent adverse events included fatigue,
nausea, dizziness, headache and rash among others. Of the 30
patients enrolled, 2 patients had conﬁrmed PR by RECIST and 10
had SD. Three patients had metabolic PR (>25% decline in the SUV
max) and 16 had SD on FDG-PET imaging [79].
Based on these data, phase II studies with this compound in com-
bination with Aromasin were planned [80], however, BIIB021 is no
longer listed on the Biogen Idec pipeline. Apparently, Biogen Idec no
longer will develop BIIB021 as they are shifting focus away from
oncology for strategic purposes, and plan to outlicense its further
development [81].
2.2.2. MPC-3100
MPC-3100 (Table 1, entry 6) is being developed by Myrexis, a
company under the umbrella of Myriad Pharmaceuticals [82]. A
phase I, modiﬁed Fibonacci, dose-escalation trial evaluated oral
daily dose of MPC-3100 for 21 days in a 28-day cycle in patients
with refractory or relapsed cancer. Single patient cohorts were stud-
ied for the ﬁrst three dose levels (50, 100, 165 mg/m2). The ﬁrst
patient treated at 245 mg/m2 developed grade 2 prerenal azotemia.
Two additional patients were therefore treated in this cohort. One
of these patients experienced a DLT of supraventricular tachycardia
and respiratory failure after day 21 dose. Patients were enrolled at
the 245 mg/m2 cohort which was expanded after the development
of the ﬁrst DLT [83]. MPC-3100 recently completed the phase 1
study and results are awaited. Due to the poor solubility and bioavail-
ability of MPC-3100, Myrexis announced the planned introduction of
a pro-drug, MPC-0767. The expected ﬁling of an IND for the pro-drug
candidate MPC-0767 is in the ﬁrst quarter of 2012 [84].
2.2.3. Debio 0932 (CUDC-305)
Scientists at Curis replaced the N3 of the purine (Fig. 1, depicted in
red on PU3) with a carbon to result in a purine-like derivative, Debio
0932 (CUDC-305) [85], which is being developed by Debiopharm
(Table 1, entry 7) [86]. In April 2010, Debiopharm initiated the
phase I trial that is designed to evaluate the MTD and safety of
Debio 0932 in patients with advanced solid tumors or lymphoma.
The ﬁrst part of this study (phase Ia) is an open-label, dose-
escalation, phase trial where the study drug will be administered
orally (25–100 mg) in both daily and every other day regimens. A
total of 80 patients are expected to be treated in the phase Ia portion.
The phase Ib portion is an expansion cohort of certain solid tumors
and/or lymphoma patients which will further assess the safety, PK
and PD of this agent at a potential phase II dose level to make a pre-
liminary assessment of anti-tumor activity. About 40 patients are
expected to be treated on this phase Ib portion. The trial is currently
ongoing and results are awaited [87].
2.2.4. PU-H71
The Chiosis group at Memorial Sloan-Kettering has discovered the
Hsp90 inhibitor PU-H71 [88–90], which is being evaluated in a phase
I clinical trial in patients with advanced solid tumors, lymphoma and
myeloproliferative disorders under license to Samus Therapeutics
(Table 1, entry 8) The primary objective is to assess the safety,
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tumors and lymphoma when administered intravenously three
times weekly for 2 weeks in a 21-day cycle. Secondary objectives
are to assess anti-tumor activity as deﬁned by response rate, CR,
partial response (PR), stable disease, duration of response, and
progression free survival (PFS), and to evaluate 124I-PU-H71 as a
non-invasive means to determine tumor PK and intratumor concen-
tration in a selected group of patients with advanced malignancies.
Exploratory objectives are to evaluate 124I-PU-H71 as a non-invasive
means to predict tumor dose–response relationships in a selected
group of patients with advanced malignancies, to evaluate changes
in tumor client proteins using optional tumor biopsies performed
pre- and post-treatment, to evaluate ex vivo the sensitivity of the
tumor to PU-H71 by performing optional tumor biopsies pre- treat-
ment and to evaluate changes in client proteins in the circulating
tumor cells pre- and post-treatment. This phase I trial began patient
accrual in early August 2011.
This agent is also being studied at a different dosing schedule at
the NCI in patients with advanced solid tumors and low-grade non-
Hodgkin's lymphoma. Patients will receive PU-H71 intravenously
weekly×2 weeks of 21-day cycle. This study will follow a modiﬁed
accelerated titration design; the accelerated phase will end when
one patient experiences a DLT or two patients experience grade 2
drug-related toxicities during the ﬁrst cycle, after which the study
will follow a standard 3+3 design. The primary objectives are to es-
tablish the safety, tolerability, MTD, recommended phase 2 dose, and
PK of PU-H71 when administered on the above mentioned schedule.
Secondary objectives are to perform pharmacodynamic (PD) studies
to ascertain the effect of PU-H71 on Hsp90 client proteins in tumor
tissue at the MTD, and on Hsp70 in tumor tissue, serum, and periph-
eral blood mononuclear cells at the MTD. PK and PD studies will be
conducted during cycle 1. Up to 10 additional patients will be entered
at the MTD to further deﬁne toxicity and perform PD studies at this
dose. Planned accrual is up to 50 patients. This study is actively
recruiting patients since June 2011 [91].
2.3. Resorcinol derivatives
RD is a macrocyclic lactone antibiotic ﬁrst isolated from the fungus
Monosporium bonorden in 1953 (Fig. 1) [92]. In addition to a resorcin-
ol moiety (depicted in red in Fig. 1), RD also contains reactive epoxide
and α,β,γ,δ-unsaturated carbonyl groups. RD is not stable in serum
and is devoid of in vivo activity, however, the resorcinol core is main-
tained in a number of molecules entering clinical trials including
NVP-AUY922, KW-2478, and AT13387 as well as STA-9090 (Table 1,
entry 9–13). While these molecules were not discovered through
direct modiﬁcation of RD they clearly resemble it by maintaining
the resorcinol core as a critical element for binding.
2.3.1. Triazole derivatives STA-9090 (Ganetespib)
STA-9090 (Table 1, entry 9) is an unspeciﬁed novel resorcinol-
containing triazole compound developed by Synta Pharmaceuticals
and has been tested in multiple clinical trials in both advanced solid
tumors and hematological malignancies.
Goldman et al. evaluated STA-9090 in a phase I trial in 35 patients
with advanced solid tumors wherein they received this agent intrave-
nously weekly for 3 weeks in a 28-day cycle. MTD was determined at
216 mg/m2. DLT was fatigue, diarrhea and elevated amylase. Other
common adverse events included abdominal pain, anemia, nausea,
constipation and dyspnea. There was 1 PR in a patient with rectal
cancer and several SD were noted in patients with gastrointestinal
stromal tumor, non-small cell lung cancer and renal cell carcinoma
[93]. Another phase I dose-escalation trial is evaluating twice weekly
dosing (2–144 mg/m2) for 3 weeks in a 28-day cycle. Forty-nine
patients have been treated so far. DLT was elevated liver enzymes.
Of the evaluable patients, 1 PR was noted in a patient with metastaticmelanoma and there were 2 SD in patients with non-small cell
lung cancer. STA-9090 was well tolerated up to 120 mg/m2; the
144 mg/m2 dose cohort has been expanded and dose escalation is
ongoing [94].
A safety and efﬁcacy phase I/II study in patients with acute
myeloid leukemia and other hematological malignancies evaluated
weekly infusions of STA-9090 for 4 consecutive weeks per cycle at 3
dose levels (120–200 mg/m2). One patient had a DLT of elevated
liver enzymes. There were no formal responses noted but one patient
with refractory acute myeloid leukemia had SD and bone marrow
blast reduction lasting 10 weeks. The recommended phase II dose
has not been identiﬁed and accrual is ongoing [95]. Another multicen-
ter, phase I trial evaluated STA-9090 administered intravenously
twice weekly at doses ranging 14–110 mg/m2 for 4 weeks. DLT in-
cluded hyponatremia, hyperbilirubinemia, elevated liver enzymes
and prolonged QTc. MTD has not been determined. Clinical responses
included hematological responses in 2 patients with chronic myeloid
leukemia (CML) and acute myeloid leukemia respectively. In addi-
tion, 4 patients with myeloﬁbrosis had SD; 1 of these responses lasted
7 months and the patient went on to receive allogenic stem cell trans-
plant [96].
A phase II trial of STA-9090 was conducted in patients with
non-small cell lung cancer. Patients received weekly infusions of
STA-9090 at 200 mg/m2 for 3 weeks in a 28-day cycle. Patients were
enrolled based on their mutation status; cohort A: EGFR, cohort B:
KRAS, cohort C: EGFR and KRAS wild type (WT) and cohort D: EGFR
and KRAS WT with adenocarcinoma histology. Additional mutational
analysis of BRAF, PIK3CA, ERBB2 and MET, as well as FISH analysis for
ALK translocation (EML4-ALK gene-rearrangement), were performed
in a subset of patients. Study design also included cohort E which
would allow patients with clinical beneﬁt in cohorts A through D to
receive weekly docetaxel therapy in addition to ganetespib after pro-
gression of disease. Primary endpoint was PFS at 16 weeks with ex-
pansion for that particular cohort. Common adverse events reported
were fatigue, diarrhea, nausea, anorexia and dyspnea which were all
manageable and easily reversible. Expansion criteria were achieved
for cohort C, including 1 PR and 7 patients with SD>16 weeks [97].
Updated results were presented at the 14th World Conference on
lung cancer in July, 2011 in Amsterdam. It was noted that 8 patients
in cohort C/D harbored the EML4-ALK-rearrangement gene (ALK
+tumors). Six out of 8 (75%) patients were crizotinib naïve and had
tumor shrinkage in the target lesions. Additionally, another patient
with ALK+tumor with crizotinib-refractory disease had impressive
tumor regressions in the lung and responded to single agent ganete-
spib. Eight of thirteen (62%) patients with KRAS mutation also
had tumor shrinkage. One patient with mixed response (16% target
lesion shrinkage and development of new lesions) rolled over to
cohort E at 8 months. A phase IIb/III trial of ganetespib and docetaxel
in second line advanced non-small cell lung cancer patients has been
initiated [98].
Similar to the patients with non-small cell lung cancer, patients
with gastrointestinal stromal tumor were also treated with STA-
9090 at 200 mg/m2 weekly for 3 weeks in a 28-day cycle. In this
Simon's two stage study design, if >4/23 patients in stage 1 had a
CBR>16 weeks, then enrollment would continue to stage 2. Hsp90
client protein levels were analyzed in pre- and post-treatment
tumor biopsies. Common adverse events noted were fatigue, diar-
rhea, nausea, vomiting and increased alkaline phosphatase. 12/23
evaluable patients had SD meeting the formal criteria to enroll to
stage 2. However, paired tumor biopsies in 4 patients did not show
prolonged inhibition of activated KIT or its downstream pathways.
Accrual has been limited to patients with PDGFRA mutations to
allow alternative schedules and combinations [99].
An open label phase II trial of STA-9090 is currently ongoing in
patients with unselected metastatic breast cancer. STA-9090 is ad-
ministered at the same dose and schedule used in patients with
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ry endpoint is to determine overall RR using RECIST 1.1 [100].
2.3.2. Isoxazole derivatives NVP-AUY922/VER52296
Workman and colleagues from the Cancer Research UK Center
for Cancer Therapeutics ﬁrst identiﬁed the resorcinol containing
pyrazole CCT018159 from a HTS of a library of 56,000 compounds
capable of inhibiting the ATPase activity of yeast Hsp90 [101]. Using
a structure-based approach, scientists at Vernalis and the Cancer
Research UK Center for Cancer Therapeutics optimized this hit into
the isoxazole NVP-AUY922/VER52296 (Table 1, entry 10) [102,103].
This compound is now being developed by Novartis and is currently
in phase I/II clinical trials in patients with relapsed or refractory
multiple myeloma and HER2+ and ER+metastatic breast cancer.
Single agent NVP-AUY922 was administered intravenously week-
ly in 28-day cycle to patients with advanced solid tumors in a phase
I study. A total of 96 patients were treated at doses ranging
2–70 mg/m2. Endpoints also included PK and PD analyses. DLT was
atrial ﬂutter, diarrhea, fatigue, darkening of vision and anorexia.
Other common adverse events included nausea (35%), vomiting
(18%), and night blindness (20%). MTD was 70 mg/m2. SD was
reported in 16 patients and 9 patients had a partial metabolic
response on FDG-PET [104]. This led to the phase II expansion in pa-
tients with HER2+ and ER+metastatic breast cancer. Preliminary
imaging and biomarker data from this phase II trial were reported
in the 2011 Annual ASCO Scientiﬁc meeting. Patients with HER2+
and ER+disease underwent FDG-PET with trastuzumab and bevaci-
zumab respectively at baseline and during treatment. Two HER2+
patients had partial metabolic response and 1 of these patients had
conﬁrmed PR by RECIST [105].
A phase I/II study to determine the MTD of NVP-AUY922 alone and
in combination with bortezomib, with or without dexamethasone, in
patients with relapsed or refractory multiple myeloma has been
completed and results are awaited [106].
Although the chemical structure of HSP990, an oral Hsp90 inhibi-
tor, has not yet been reported, it is claimed to be a follow-up com-
pound of NVP-AUY922. A phase I trial is evaluating HSP990 when
administered either weekly or twice weekly in patient with advanced
solid tumors. Endpoints include MTD, DLT, efﬁcacy, PK and PD. The
study is currently actively recruiting patients [107]. Another phase I
trial is assessing the once weekly dose in adult Japanese and Korean
patients with advanced solid tumors [108].
2.3.3. Other resorcinol derivatives
2.3.3.1. KW-2478. The novel resorcinol analog KW-2478 was discov-
ered by Kyowa Hakko Kirin Pharma through “a unique lead optimiza-
tion strategy, including microbial screening, X-ray crystallography,
cell-based screening, and in vivo models” (Table 1, entry 12) [109].
A phase I safety, PK and PD study of KW-2478 were recently complet-
ed in patients with relapsed/refractory multiple myeloma, chronic
lymphocytic leukemia or B-cell non-Hodgkin's lymphoma. KW-2478
(14–99 mg/m2) was administered intravenously daily on days 1–5
of a 14-day cycle. There were no DLTs observed up to 99 mg/m2.
Drug related toxicities included grade 1/2 hypertension in one patient
and grade 3 QTc prolongation in another. The study is ongoing at
a dose of 132 mg/m2 and further dose-escalation is planned [110].
Another phase I/II trial is evaluating this agent in combination with
bortezomib when administered on days 1, 4, 8, 11 of a 21-day cycle
in patients with relapsed and refractory multiple myeloma [111].
2.3.3.2. AT-13387. AT13387 was discovered by scientists at Astex
following optimization of a resorcinol-containing lead generated
through a fragment-based drug discovery approach (Table 1, entry
13) [112,113]. Three phase I trials are evaluating this agent in various
dosing schedules including weekly or twice weekly intravenousinfusions for 3 weeks in a 28-day cycle [114] and twice a week
(2 days in a row) for the ﬁrst 3 weeks in a 28-day cycle [115,116]
in patients with advanced solid tumors. It is also being evaluated
with or without Imatinib in a multicenter, randomized phase II
study in patients with advanced gastrointestinal stromal tumor who
have progressed following treatment with TKIs. AT-13387 will be ad-
ministered IV weekly for 3 weeks of a 28-day cycle. Primary endpoint
of this trial is to assess reduction/stabilization of tumor at 4 months
using RECIST 1.1 criteria [117].
2.4. Dihydroindazolone derivatives
SNX-5422 is a pyrazole-containing Hsp90 inhibitor that was
discovered by scientists at Serenex following optimization of a hit
identiﬁed using an ATP-afﬁnity column (Table 1, entry 14) [118].
This column was used to ﬁrst load ATP-binding proteins, then was
challenged with a library of structurally diverse 8000 compounds
to identify molecules capable of displacing unspeciﬁed proteins
from the column. Hsp90 was identiﬁed as the target of an initial hit
compound. SNX-5422 is actually the glycine prodrug of SNX-2112
(Fig. 1). In May 2007, Serenex Inc started a phase I trial for SNX-
5422 in patients with solid tumor and lymphoma. SNX-5422
(4–21.28 mg/m2) was administered orally every other day daily for
21 days in a 28-day cycle. Objectives were to determine MTD and
PK of this agent. There were no DLTs observed among the 11 patients
treated. Grade 1 toxicities included nausea and fatigue. The trial was
enrolling at 21.28 mg/m2 [119]. In March 2008, Pﬁzer Inc announced
that it has entered into an agreement to acquire Serenex Inc [120].
Later, the development of SNX-5422 was discontinued based on
reports of ocular toxicity and the potential for irreversible retinal
damage [121].
2.5. Others
Other Hsp90 inhibitors include DS-2248 (Daiichi Sankyo, Inc;
undergoing phase I evaluation) [122] and XL-888 (Exelixis; sponsor
has decided to terminate the safety study of this agent) [123]. The
structures for these two inhibitors have not been disclosed.
3. Assays for monitoring response to Hsp90 inhibition in clinic
Several clinical assays have been developed to assess Hsp90-target
inhibition, mainly by measuring the levels of a number of Hsp90
onco-client proteins from samples obtained pre- and post-Hsp90
inhibitor administration. As mentioned, Hsp90 inhibition causes the
proteasomal degradation of such client proteins [1,2,12]. Hsp70 in-
duction, another read-out of Hsp90 inhibition established in several
cancer models, was also evaluated.
Most such PD assays to date have been performed on peripheral
blood mononuclear cells (PBMCs). Several potential biomarkers,
such as CDK4, Raf-1, c-KIT reduction and Hsp70 induction were mea-
sured in these studies. While PD monitoring of PBMCs has provided a
readily accessible and reproducible index of in vivo biologic activity of
Hsp90 inhibitors in clinical trials, the current consensus from these
studies is that drug effects in these cells do not predict tumor-
speciﬁc activity [18,53,54].
This is not surprising in light of a body of evidence showing a
higher sensitivity of cancer cells to Hsp90 inhibition when compared
to normal cells, as well as preferential accumulation of these inhibi-
tors in tumor cells rather than normal cells [124–126]. As a means
of explanation, Kamal et al. proposed that Hsp90 in tumors exists en-
tirely in multi-chaperone complexes of high afﬁnity for certain small
molecule inhibitors, whereas Hsp90 from normal tissues is in a latent,
uncomplexed state of low inhibitor binding potential [123]. Recent
work by Moulick et al. substantiates but also signiﬁcantly extends
this view by proposing that Hsp90 forms biochemically distinct
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cancer cell Hsp90 retains “housekeeping” chaperone functions similar
to normal cells, whereas a functionally distinct Hsp90 pool enriched
or expanded in cancer cells speciﬁcally interacts with oncogenic pro-
teins required to maintain tumor cell survival. This Hsp90 fraction
perhaps represents a cell stress speciﬁc form of chaperone complex,
that is expanded and constitutively maintained in the tumor cell
context, and that may execute functions necessary to maintain the
malignant phenotype. Such roles are not only to regulate the folding
of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric pro-
teins (i.e. Bcr-Abl) [1–3], but also to facilitate scaffolding and complex
formation of molecules involved in aberrantly activated signaling
complexes (i.e. STAT5, BCL6) [88,125]. The abundance of this tumor
Hsp90 species, which is not dictated by Hsp90 expression alone, is
potentially predictive of the cell's sensitivity to Hsp90 inhibition
[125].
Preclinical data also suggest that the levels of soluble IGFBP2 and
HER2 extracellular domain levels [127] or serum Hsp70 might be a
useful PD marker of drug response [128], however, the utility of
these potential biomarkers has yet to be validated in clinical settings
[129].
The use of biopsies to measure PD changes has also been
attempted in an effort to assay target modulation [16], but remains
limited because of the logistical and ethical issues associated with
repeated invasive procedures. Studies in melanoma patients noted
changes in biomarkers in patients that experienced prolonged stable
disease when treated with 17-AAG [16] at the dose levels 320 and
450 mg/m2/week. When 17-AAG was administered i.v. once week-
ly×6 weeks at 450 mg/m2 dose and schedule of 17-AAG, the effects
of 17-AAG on Raf-1 kinase expression were short-lived, and no objec-
tive anti-melanoma responses were seen [25], suggesting collectively
that at this dose and schedule, the tumor Hsp90 target was not opti-
mally inhibited.
As an alternative to tumor biopsies, changes in the levels of tumor
HER2 and VEGF levels are now being investigated non-invasively by
PET using gallium-68 or zirconium-89 labeled antibodies [130–132].
This sensitive assay is able to monitor tumor receptor expression in
real time following systemic Hsp90 inhibitor administration, and
is currently incorporated in several ongoing clinical studies with
Hsp90 inhibitors [132–134]. While results of these studies are
awaited, it is evident that the use of these assays remains limited to
tumors that express these markers.
PET with [18F]-FDG was also tested as an assay to measure early
response to Hsp90 therapy. Preclinical studies in HER2 tumors
suggested no changes in FDG-PET at 24 hour post Hsp90 inhibitor
administration, in contrast to HER2 PET [135]. When incorporated
into a phase I trial of IPI-504 in patients with metastatic TKI-
resistant gastrointestinal stromal tumor who received the Hsp90
inhibitor on days 1, 4, 8 and 11 of a 21 day cycle, serial monitoring
with 18FDG-PET/CT imaging at baseline, day 11, and day 21, showed
a reduced FDG-PET signal. Reactivation of tumor FDG uptake correlat-
ed with planned breaks in drug administration, and the signal
decreased again when treatment resumed [136]. On this trial only
SD was noted and it remains unclear whether a complete FDG uptake
inhibition rather than reduction in uptake is needed to result in CR
and PR. Metabolic PR and SD have been reported with BIIB021 and
NVP-AUY922 using FDG-PET imaging [79,104]. These data suggest
that, at least in highly glycolytic tumors, FDG-PET may provide a
useful assay to measure Hsp90 tumor inhibition over a longer drug
administration time.
The Hsp90 inhibitor PU-H71 has an endogenous iodine atom
(127I), which can be conveniently replaced with the PET radionuclide
124I to result in the imaging agent 124I-PU-H71. Since the PET imaging
agent is virtually identical to PU-H71, the use of this radioligand
allows for assessing drug distribution by non-invasive PET imaging.
A phase 0 trial of 124I-PU-H71 which evaluates the radiationdosimetry, metabolism and biodistribution of this PET agent is cur-
rently ongoing [137]. The purpose of this study is to see how PU-
H71 accumulates and how long it lasts inside tumors. The results of
the phase 0 trial will help plan how to use PU-H71 in the phase I set-
ting; speciﬁcally it will allow optimization of the PET agent to assess
tumor pharmacokinetics of PU-H71 in the phase I study. The PET
assay will also be investigated in the phase I to evaluate tumor
dose–response correlations by measuring PU-H71 tumor concentra-
tions for up to 48 hours post co-infusion of PU-H71 with 124I-PU-H71
[138]. Together, this may provide useful information on identifying
tumors more likely to respond to PU-H71 therapy and in designing
most optimal dose and schedules for the administration of the
Hsp90 inhibitor.
4. Conclusion
Given their potential to degrade a number of different oncopro-
teins and affect multiple signaling pathways, Hsp90 inhibitors have
been hypothesized to be active in a wide variety of cancers. To date,
the greatest clinical activity as evidenced by objective tumor regres-
sions, has been observed with the geldanamycin analog tanespimycin
when given in combination with trastuzumab to patients with
HER2+ metastatic breast cancer. Pre-clinically, HER2 is among the
most sensitive client proteins to Hsp90 inhibition and this may
account for the activity observed in this setting. Recently, objective
tumor responses were reported with ganetespib in all tumors that
harbored the ALK rearrangement. This further emphasizes the tar-
geted approach of Hsp90 inhibition, in that responses are perhaps de-
pendent upon addiction of the tumors to Hsp90 client oncoproteins.
While these results validate Hsp90 inhibition as a relevant anti-
cancer strategy, the full potential of these inhibitors to be active in a
broader spectrum of tumor types has yet to be achieved. This differ-
ential response could be because we are unable to select patients
who might best beneﬁt from therapy and perhaps have not success-
fully optimized the dosing and scheduling of this class of agents.
As a class, Hsp90 inhibitors demonstrate rapid clearance from
normal tissues and the blood compartment with prolonged retention
in tumors, hence traditional serum pharmacokinetics may be insufﬁ-
cient to guide dosing and scheduling [4,88–90,103,125,139]. Addition-
ally, the current drug development paradigm based on identifying
maximum tolerated dose may not be applicable in the case of these
inhibitors where target modulation is critical to producing their anti-
tumor effects. In order to optimally deliver Hsp90 inhibitor therapy,
evaluation of the effects of these agents at the level of the tumor
(including client protein modulation) is essential. To this end, tumor
biopsies and novel targeted imaging studies must be incorporated
into future clinical trials of these drugs and efforts at identifying robust
biomarkers of response and resistance will be crucial next steps in
rationalizing the clinical development of the growing list of Hsp90
inhibitors. Ultimately this investment into understanding the funda-
mentals of drug delivery and patient selection for these unique inhib-
itors will allow the next generation of Hsp90 targeted therapies to
realize their full potential and promise as anti-cancer therapeutics.
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